Original Research

The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells

Wang L, Yang Q, Peng S, Liu X

OncoTargets and Therapy 2019, 12:5359-5373

Published Date: 8 July 2019